The Journal of the Association of Physicians of India
-
J Assoc Physicians India · May 2007
Comparative StudyTraditional journal club: a continuing problem.
To evaluate the pattern, motivation and facilities for choosing journal club topics by residents in two medical institutions in India. ⋯ In both the institutions surveyed, journal clubs were of traditional type. Better infrastructure and training at PGI were not reflected in quality of journal club. Successful journal club should focus on current, real patient's problem of most interest to the group.
-
J Assoc Physicians India · Apr 2007
Case ReportsHospital-based case series of 175 cases of serologically confirmed brucellosis in Bikaner.
To study the clinical spectrum of brucellosis in Bikaner (Northwest India). ⋯ Brucellosis is an important emerging zoonotic disease but it is often under-diagnosed due to lack of suspicion and diagnostic facilities despite the fact that cattle farming (an important high risk group) is one of the main occupation in rural area. This report should infuse the awareness about this reemerging disease specifically in high-risk group.
-
Live kidney donation is an established form of organ donation but carries the risk of an unnecessary surgery in a normal individual for the benefit of the recipient. Long term effects of nephrectomy have not been studied in Indian donors so far. ⋯ This pilot study reaffirms the safety of live kidney donation. There was a fall in GFR with consequent increase in renal length postnephrectomy. The long-term implications of the minimal increase in proteinuria and rise in blood pressure need to be evaluated in larger cohort of donors over a longer period of time. This study underscores the need for initiating a donor registry to achieve this objective.
-
J Assoc Physicians India · Feb 2007
Hematological and molecular response evaluation of CML patients on imatinib.
The BCR-ABL tyrosine kinase is a well-validated therapeutic target in Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase inhibitor is highly effective at the hematological, cytogenetic and molecular level in CML. ⋯ Imatinib mesylate is highly effective in the treatment of chronic phase CML and so should be considered as the drug of first choice in CML. Molecular response evaluation after six months can predict the subsequent molecular response and can also be usedas a surrogate monitor of the marrow cytogenetic response to imatinib therapy in CML.